Latest Apogenix GmbH Stories
Apogenix - Positive Results from APG101 Phase II Clinical Trial Published in Clinical Cancer Research
HEIDELBERG, Germany, Oct.
Apogenix' APG101 Demonstrates Significant Prolongation of Overall Survival in Biomarker-Positive Patients in Phase II Trial for the Treatment of Recurrent Glioblastoma
Topline Data Will Be Presented at Biotech Showcase HEIDELBERG, Germany, Jan.
Apogenix to Present Phase II Results with APG101 for the Treatment of Recurrent Glioblastoma at Biotech Showcase in San Francisco
HEIDELBERG, Germany, Jan.